Cancer News and Research

Latest Cancer News and Research

Hybrigenics receives EUR 800,000 payment from Oseo

Hybrigenics (ALHYG), a bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialized in protein interactions services, today announces it has received EUR 800,000 as the second and last payment of a EUR 1.4 million refundable grant contract originally signed with France’s innovation agency, Oseo Innovation, in 2008.

2 Dec 2010

New clue in leukemia mystery

There is new hope for people with acute myelogenous leukemia (AML), a fast-growing cancer of the blood and bone marrow. Research led by Weill Cornell Medical College and published today in the online edition of the journal Cancer Cell reveals a surprising and unexpected cancer-causing mechanism. The investigators discovered that newly identified mutant enzymes in AML create a chemical poison to cause leukemia. Their findings should prove useful in treating patients by providing a molecular target against which to develop new drugs against one subset of AML as well as other cancers.

2 Dec 2010

MicroRNA linked to mosquito blood digestion and egg development identified

Each year, dengue fever infects as many as 100 million people while yellow fever is responsible for about 30,000 deaths worldwide. Both diseases are spread by infected female Aedes aegypti mosquitoes, which require vertebrate blood to produce eggs. The blood feeding and the egg development are tightly linked to how the mosquito transmits the disease-causing virus.

2 Dec 2010

First Edition: December 2, 2010

Today's health policy headlines include news about how the debt panel's plan would boost costs for seniors on Medicare; how parts of the GOP are making clear their positions regarding health reform "repeal and replace" strategy; and how limited health plans faced critics at a Senate hearing.

2 Dec 2010

News segment highlights value of hyperthermia for treatment of breast cancer

BSD Medical Corp. today reported that hyperthermia treatment delivered at Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas was highlighted in a television segment titled, "Turning up the heat on breast cancer," which aired on WFAA-TV, a Dallas/Fort Worth ABC affiliated television station.

2 Dec 2010

Freedom to Breathe Act improves health without imposing economic burden on hospitality

New research released in the December 2010 supplement to the American Journal of Preventive Medicine (AJPM) concludes that Minnesota's statewide smoke-free law has not adversely affected bar and restaurant employment. The research adds to the growing body of evidence on the Freedom to Breathe Act's success and offers the first analysis of independent data from the Minnesota Department of Employment and Economic Development.

2 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol), a standard chemotherapy regimen, will be presented during the 33rd Annual San Antonio Breast Cancer Symposium (SABCS) being held December 8-12, 2010 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

2 Dec 2010

Study finds inconsistency in OTC medications for children

Instructions on boxes and bottles of over-the-counter (OTC) medicines for children in the United States are confusing and hard for parents to understand and follow, according to a study in the December 1 issue of JAMA.

2 Dec 2010

Mount Sinai’s instructor receives Liz Tilberis Grant from OCRF

AnaLisa DiFeo, PhD, Instructor in the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine, has been honored by the Ovarian Cancer Research Fund (OCRF) with the Liz Tilberis Grant.

2 Dec 2010

UMDNJ experts to discuss IOM guidelines on vitamin D

For media covering the new Institute of Medicine (IOM) guidelines on vitamin D, several experts at the University of Medicine and Dentistry of New Jersey (UMDNJ) are available for comment. The new guidelines updated the dietary reference intakes (DRIs) that the IOM established more than a decade ago and represent a significant change from previous limits.

2 Dec 2010

St. Jude ICU honored with Beacon Award for Critical Care Excellence for second consecutive year

The Intensive Care Unit (ICU) at St. Jude Children's Research Hospital has been recognized for the second consecutive year with the Beacon Award for Critical Care Excellence given by the American Association of Critical-Care Nurses (AACN). In 2009, the St. Jude ICU became Tennessee's first ICU to win the honor.

2 Dec 2010

Study reveals role of VSV in killing cancer cells through turning off major survival signal

Researchers from Boston University School of Medicine (BUSM) have identified a mechanism by which specific viruses acting as oncolytic agents can enter and kill cancer cells. This finding, which is currently featured in an online edition of the Journal of Virology, could help lead to the development of more targeted treatments against many types of cancer.

2 Dec 2010

Lexus of Tacoma donates $3,000 to Carol Milgard Breast Center

Today, Lexus of Tacoma at Fife presented the Carol Milgard Breast Center, a joint collaboration of the Multicare Health System, the Franciscan Health System and TRA Medical Imaging, a company-sponsored donation in the amount of $3,000.

2 Dec 2010

People with mental health diagnoses receives poor quality of preventive mass screening

Dr Alex Mitchell, of the Department of Cancer Studies and Molecular Medicine at the University of Leicester, led the study which has been published in the journal General Hospital Psychiatry. Dr Mitchell said preventive screening refers to population based medical tests such as mammography, colonoscopy, blood pressure testing or cholesterol levels to detect conditions such as cancer, diabetes or heart conditions. These screening programmes are typically administered widely in order to help with early detection or prevention and have been credited with improving outcomes of several key medical conditions.

2 Dec 2010

Lipids react and change to bacterial stimulus, trigger cell's immune response

For the first time, scientists have described not only the identities and quantities of fat species in a living mammalian cell in this case, a mouse macrophage or white blood cell but they also report how these lipids react and change over time to a bacterial stimulus triggering the cell's immune response.

2 Dec 2010

Research may lead to new treatment strategies for Graves' disease

Researchers at the National Institutes of Health have identified a compound that prevents overproduction of thyroid hormone, a finding that brings scientists one step closer to improving treatment for Graves' disease.

2 Dec 2010

Stemline to feature SL-401 clinical efficacy at ASH Annual Meeting

Stemline Therapeutics, Inc. today announced that two abstracts featuring SL-401 clinical efficacy in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and pre-clinical activity in chronic myeloid leukemia (CML) have been selected for presentation at the upcoming 52nd Annual Meeting of the American Society of Hematology (ASH) to be held in Orlando, FL from December 4-7, 2010.

2 Dec 2010

New radiation-free device to detect breast cancer

A new device may enable breast cancer screening and cancer detection in populations where mammography is not widely available or successful, including women in developing countries, and those under the age of 40.

2 Dec 2010

FDA advisory committee votes against Avodart sNDA for prostate cancer risk reduction

GlaxoSmithKline today announced the results of a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the supplemental New Drug Application (sNDA) for Avodart® (dutasteride) for reducing the risk of prostate cancer in men at risk for the disease, defined as those who have had a prior negative biopsy due to clinical concern and have an elevated serum prostate-specific antigen (PSA).

2 Dec 2010